Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 15/20 | 0.54 |
| ▸ | EZH1 | Q92800 | 10/20 | 0.54 |
| ▸ | EED | O75530 | 3/20 | 0.48 |
| ▸ | SUZ12 | Q15022 | 3/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | RBBP4 | Q09028 | 2/20 | 0.44 |
| ▸ | RBBP7 | Q16576 | 2/20 | 0.44 |
| ▸ | AEBP2 | Q6ZN18 | 2/20 | 0.44 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.44 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2595707 | 0.92 | EZH2 (0.55) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL2594712 | 0.92 | EZH2 (0.64) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL2594938 | 0.89 | EZH2 (0.51) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL2591361 | 0.87 | EZH2 (0.65) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL2595194 | 0.86 | EZH2 (0.51) | EZH2EZH1EEDSUZ12 | |
| SCHEMBL2594702 | 0.85 | EZH2 (0.73) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL2594666 | 0.83 | EZH2 (0.51) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL12180146 | 0.83 | EZH2 (0.44) | EZH2EZH1EEDSUZ12RBBP4 | |
| SCHEMBL14718173 | 0.81 | EZH2 (0.65) | EZH2EZH1EEDSUZ12HDAC1 | |
| SCHEMBL17970467 | 0.81 | EZH2 (0.43) | EZH2EZH1EEDSUZ12RBBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2773754-B1 | Compounds for use in the treatment of T-cell mediated diseases | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2016-08-03 | — | — | EP | claimed |
| EP-2566327-A1 | INDOLES | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | claimed |
| WO-2011140324-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | claimed |
| US-9649307-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-9649307-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160296518-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160296518-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2016-10-13 | — | — | US | disclosed |
| US-9446041-B2 | Method of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-9402836-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160074394-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE LLC | 2016-03-17 | — | — | US | disclosed |
| US-9242962-B2 | Method of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-20140256739-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE LLC | 2014-09-11 | — | — | US | disclosed |
| EP-2773754-A1 | METHOD OF TREATMENT | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2014-09-10 | — | — | EP | disclosed |
| US-8536179-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2013-09-17 | — | — | US | disclosed |
| US-8536179-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2013-09-17 | — | — | US | disclosed |
| WO-2013067296-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013067296-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| US-20130053397-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| US-20130053397-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| WO-2011140324-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160074394-A1 | METHOD OF TREATMENT | EZH1, EZH2, SUV39H2 | EZH2 2/4885EZH1 1/4885EED 15/4885 |
| US-20140256739-A1 | METHOD OF TREATMENT | EZH1, EZH2, SUV39H2 | EZH2 2/4885EZH1 1/4885EED 15/4885 |
| US-20130053397-A1 | INDOLES | IDO1, IDO2, INMT | EZH2 239/4885EZH1 677/4885EED 3258/4885 |
| US-20160296518-A1 | INDOLES | IDO1, IDO2, INMT | EZH2 257/4885EZH1 669/4885EED 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.